Figure 4.

SIRT1 mediates the synthesis of triglycerides in NAFLD mice, which is associated with QKI 5 and the PPARα/FoxO1 signaling pathway in vitro. The inhibitor of FOXO1 (AS1842856) was used in the present study. The results demonstrated that the inhibitor of FOXO1 suppressed FOXO1 and PPARα, and this was reversed by SRT1720. AS1842856 did not inhibit the expression of SIRT1 or QKI 5. Hepatic SIRT1 regulated the expression of QKI 5 via the PPARα/FOXO1 signaling pathway. NAFLD, non-alcoholic fatty liver disease; PPARα, peroxisome proliferator-activated receptor α; FOXO1, Forkhead box protein O1; QKI 5, Quaking 5; SIRT1, Sirtuin 1.